Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

mRNA vaccines can enhance immunotherapy efficacy by activating the immune system, improving outcomes in hard-to-treat tumors. mRNA COVID-19 vaccines enhance immune responses, improving cancer ...

Menopause care is not one-size-fits-all, especially for gender nonconforming individuals, including transgender, nonbinary ...

Serum DR-70 levels are higher in bladder cancer patients, especially in muscle-invasive cases, indicating potential for diagnosis and staging. Current diagnostic methods for bladder cancer are ...

Newly analyzed data from Japan adds to the evidence that COVID-19 may increase the risk of shingles.

Managed Healthcare Executive interviewed OneHome’s Noel Gilliam, Vice President of Value-Based Product Design, to discuss the ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

Veterans who enter the healthcare workforce have a 29% higher chance at promotion and have a 14% higher retention rate than ...

Patients with advanced melanoma who received fecal microbiota transplants using healthy donor stool alongside standard immunotherapy survived more than four years, according to final results from an ...

Education on biosimilar safety and effectiveness, and automatic substitution laws, are essential for increased uptake.

Expert discusses how the prevalence of chronic kidney disease (CKD), as reflected by decreased estimated glomerular ...